AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38055641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid Healthy Eating Index (HEI ≥ 47.94 and < 58.89)
Number of subjects: 119
Study 38055641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Healthy Eating Index (HEI < 47.94)
Number of subjects: 119
Study 38055641 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugar ≤ 10% of calories
Number of subjects: 119
Study 38055641 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percentage of calories from fat
Number of subjects: 119
Study 38055647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal cholestasis
Number of subjects: 165
Study 38055647 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to liver transplant
Number of subjects: 165
Study 38055647 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulopathy and varices
Number of subjects: 165
Study 38056100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic + Resistance Exercises (AE + RE)
Number of subjects: 90
Study 38056100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 90
Study 38056100 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 90
Study 38056411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Number of subjects: 77
Study 38056411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study 38056467 — intervention group
Group type: EXPERIMENTAL
Intervention: Double ABCX-based psychotherapy
Number of subjects: 201
Study 38056467 — intervention group
Group type: COMPARATOR
Intervention: Control group (CoG)
Number of subjects: 201
Study 38056464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexmarilimab
Number of subjects: 138
Study 38056546 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve
Number of subjects: 900
Study 38056546 — intervention group
Group type: COMPARATOR
Intervention: Clinical surveillance
Number of subjects: 900
Study 38056770 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tool for managing oral anticoagulation (visualized in intervention centers)
Number of subjects: 44556
Study 38056772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB) in ACS
Number of subjects: 2083
Study 38056772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB) in CCS
Number of subjects: 2083
Study 38056900 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) combined with adenosine pathway inhibitor oleclumab and neo-adjuvant immuno-chemotherapy (paclitaxel, doxorubicin/cyclophosphamide, durvalumab)
Number of subjects: 6
Study 38056935 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 168
Study 38056935 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 168
Study 38056945 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-supported stroke prevention programme (n=52)
Number of subjects: 104
Study 38056945 — intervention group
Group type: COMPARATOR
Intervention: Ordinary primary healthcare (PHC) services
Number of subjects: 104
Study 38057072 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 192
Study 38057072 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 192
Study 38057314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (N)
Number of subjects: 52
Study 38057314 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab + nab-paclitaxel + carboplatin (N/C)
Number of subjects: 52
Study 38057377 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS group (10 mg/kg/h propofol infusion adjusted to keep the BIS value between 40 and 60)
Number of subjects: 130
Study 38057377 — intervention group
Group type: COMPARATOR
Intervention: Bolus group (0.5 mg/kg of propofol when necessary)
Number of subjects: 130
Study 38057377 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS group
Number of subjects: 130
Study 38057377 — intervention group
Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 130
Study 38057574 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal singing
Number of subjects: 30
Study 38057636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa plus miglustat (20 mg/kg intravenous-infused cipa plus 260 mg oral mig biweekly)
Number of subjects: 29
Study 38057656 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200) + MTX
Number of subjects: 0
Study 38057656 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200) + csDMARDs
Number of subjects: 0
Study 38057656 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab + MTX
Number of subjects: 0
Study 38057656 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 38057662 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 signalling axis intervention, specific details not provided
Number of subjects: 0
Study 38057695 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural nalbuphine (2 ml, 10 mg)
Number of subjects: 69
Study 38057695 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural dexmedetomidine (2 ml, 100 µg)
Number of subjects: 69
Study 38057695 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (10 ml 0.25% + 2 ml normal saline)
Number of subjects: 69
Study 38057709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2)
Number of subjects: 72
Study 38057709 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 72
Study 38057709 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 72
Study 38057772 — intervention group
Group type: EXPERIMENTAL
Intervention: LXI-15029, 110 mg BID (maximum tolerated dose)
Number of subjects: 24
Study 38057772 — intervention group
Group type: EXPERIMENTAL
Intervention: LXI-15029
Number of subjects: 24
Study 38057820 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 67
Study 38057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg tablet) with iftar meal during Ramadan
Number of subjects: 50
Study 38057844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vildagliptin)
Number of subjects: 50
Study 38057844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 50
Study 38057875 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole intravenously
Number of subjects: 4800
Study 38057875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4800
Study 38057919 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 2398
Study 38057919 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB3 vaccine
Number of subjects: 2398
Study 38057927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intervention modalities for S. aureus bloodstream infection
Number of subjects: 0
Study 38057927 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 38057930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle and 1st metatarsophalangeal (MTP) joint mobilisations and home-based stretches
Number of subjects: 61
Study 38058024 — intervention group
Group type: EXPERIMENTAL
Intervention: Y2TEC intervention (12 sessions, 20-30 minutes each, delivered via videoconferencing and text messaging)
Number of subjects: 0
Study 38058356 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNAs as a therapeutic intervention
Number of subjects: 0
Study 38058356 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNAs as a diagnostic tool
Number of subjects: 0
Study 38058646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy program using elastic bands (16 sessions, 45 minutes each)
Number of subjects: 35
Study 38058646 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle (control group)
Number of subjects: 35
Study 38058795 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.1, 0.2, or 0.4 mg
Number of subjects: 122
Study 38058795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 38059202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) at gallbladder meridian acupoint (GBA)
Number of subjects: 60
Study 38059202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) at non-acupoint (NA)
Number of subjects: 60
Study 38059202 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 60
Study 38059206 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work (RTW) program
Number of subjects: 70
Study 38059206 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study 38059368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 817
Study 38059368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study 38059497 — intervention group
Group type: EXPERIMENTAL
Intervention: Arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2)
Number of subjects: 490
Study 38059497 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin (400 mg/m2 given as a single intravenous infusion)
Number of subjects: 490
Study 38059497 — intervention group
Group type: EXPERIMENTAL
Intervention: Arfolitixorin
Number of subjects: 490
Study 38059497 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin
Number of subjects: 490
Study 38059611 — intervention group
Group type: EXPERIMENTAL
Intervention: Burr hole trepanation with burr hole covers
Number of subjects: 78
Study 38059611 — intervention group
Group type: COMPARATOR
Intervention: Burr hole trepanation without burr hole covers (control)
Number of subjects: 78
Study 38059635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ceftibuten
Number of subjects: 0
Study 38059635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38059722 — intervention group
Group type: EXPERIMENTAL
Intervention: 2021 ERC/ESICM algorithm for neuroprognostication with GCS-M 1-3
Number of subjects: 794
Study 38059722 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadening criteria to include patients with ongoing sedation
Number of subjects: 794
Study 38059722 — intervention group
Group type: EXPERIMENTAL
Intervention: Including all unconscious patients (GCS-M 1-5) regardless of sedation
Number of subjects: 794
Study 38059837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TBI
Number of subjects: 903
Study 38059837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TBI (ages 28 to 40)
Number of subjects: 903
Study 38059837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TBI (ages 25 to 27 and 28 to 40)
Number of subjects: 903
Study 38059837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TBI (younger age group)
Number of subjects: 903
Study 38059837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild TBI (older age group)
Number of subjects: 903
Study 38059896 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 62
Study 38059896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 38059899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy after breast cancer
Number of subjects: 4732
Study 38059932 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video-based positive mood intervention (fixed content)
Number of subjects: 654
Study 38059932 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video-based positive mood intervention (participant choice)
Number of subjects: 654
Study 38059932 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 654
Study 38059932 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both interventions and usual care)
Number of subjects: 654
Study 38059944 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Therapy (ST)
Number of subjects: 118
Study 38059944 — intervention group
Group type: COMPARATOR
Intervention: Expressive Techniques (SET)
Number of subjects: 118
Study 38059943 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0
Study 38059943 — intervention group
Group type: COMPARATOR
Intervention: Standard care as usual (SAU)
Number of subjects: 0
Study 38059946 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.60 g/kg alcohol during late follicular phase (E2 elevated)
Number of subjects: 50
Study 38059946 — intervention group
Group type: COMPARATOR
Intervention: Placebo during early follicular phase (E2 low)
Number of subjects: 50
Study 38060016 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video prior to amniocentesis
Number of subjects: 100
Study 38060016 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study 38060020 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation training
Number of subjects: 0
Study 38060020 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38060066 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-FUS (2 Gy)
Number of subjects: 6
Study 38060066 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-FUS
Number of subjects: 6
Study 38060066 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 6
Study 38060077 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 63
Study 38060077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 63
Study 38060077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 38060092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-eluting implant (n = 51)
Number of subjects: 154
Study 38060092 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-eluting implant (n = 54)
Number of subjects: 154
Study 38060092 — intervention group
Group type: COMPARATOR
Intervention: Timolol (n = 49)
Number of subjects: 154
Study 38060195 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of radiotherapy with endocrine therapy for 5 years
Number of subjects: 200
Study 38060199 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy (atezolizumab 840 mg, ipatasertib 400 mg/day, paclitaxel 80 mg/m2 or nab-paclitaxel 100 mg/m2)
Number of subjects: 317
Study 38060199 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy
Number of subjects: 317
Study 38060250 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 226
Study 38060250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 226
Study 38060250 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 226
Study 38060285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hombres Saludables PA intervention arm
Number of subjects: 38
Study 38060285 — intervention group
Group type: COMPARATOR
Intervention: Nutrition and wellness attention contact control arm
Number of subjects: 38
Study 38060340 — intervention group
Group type: EXPERIMENTAL
Intervention: IGV-001
Number of subjects: 0
Study 38060340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38060453 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of multimodal prehabilitation (supervised physical training, nutritional support, medical optimization)
Number of subjects: 40
Study 38060453 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 40
Study 38060545 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational video prescriptions about BPD
Number of subjects: 100
Study 38060545 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational video prescriptions about non-BPD mental health topics
Number of subjects: 100
Study 38060549 — intervention group
Group type: EXPERIMENTAL
Intervention: CSMT
Number of subjects: 320
Study 38060549 — intervention group
Group type: COMPARATOR
Intervention: Sham CSMT
Number of subjects: 320
Study 38060549 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 320
Study 38060549 — intervention group
Group type: COMPARATOR
Intervention: Placebo medicine
Number of subjects: 320
Study 38060584 — intervention group
Group type: EXPERIMENTAL
Intervention: 'sit less, move more, sleep better' program for up to 1 hour/day, 5 days/week, for 6 weeks
Number of subjects: 50
Study 38060584 — intervention group
Group type: COMPARATOR
Intervention: usual inpatient and early supported stroke discharge care
Number of subjects: 50
Study 38060611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified screening strategy combining nurse-driven screening for asymptomatic/paucisymptomatic patients with routine practice
Number of subjects: 138352
Study 38060611 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control) including screening for symptomatic or hospitalized patients
Number of subjects: 138352
Study 38060997 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) with the MitraClip™ device plus guideline-directed medical therapy (GDMT)
Number of subjects: 567
Study 38060997 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 567
Study 38061041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (perioperative, 5 weeks or more preoperatively and 12 months postoperatively)
Number of subjects: 186
Study 38061041 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 186
Study 38061271 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg ARA and 50 mg/kg DHA (ARA:DHA group)
Number of subjects: 120
Study 38061271 — intervention group
Group type: COMPARATOR
Intervention: Medium chain triglycerides (control)
Number of subjects: 120
Study 38061288 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 287
Study 38061339 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerna™ TME Panel biomarker-positive patients (IA subtype)
Number of subjects: 22
Study 38061346 — intervention group
Group type: EXPERIMENTAL
Intervention: VExUS-guided decongestion
Number of subjects: 140
Study 38061346 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical evaluation (Control)
Number of subjects: 140
Study 38061367 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens)
Number of subjects: 416
Study 38061367 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX-24 (2·2 μg)
Number of subjects: 416
Study 38061367 — intervention group
Group type: COMPARATOR
Intervention: PCV20
Number of subjects: 416
Study 38061370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once per day
Number of subjects: 13970
Study 38061370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study 38061376 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug nevirapine-based ART (cohort 1)
Number of subjects: 440
Study 38061376 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug nevirapine-based prophylaxis followed by three-drug nevirapine-based ART (cohort 2)
Number of subjects: 440
Study 38061378 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-GE
Number of subjects: 97
Study 38061378 — intervention group
Group type: COMPARATOR
Intervention: Duodenal stent
Number of subjects: 97
Study 38061372 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6609
Study 38061372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609
Study 38061371 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6609
Study 38061448 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS2+™ pathway
Number of subjects: 1929
Study 38061448 — intervention group
Group type: COMPARATOR
Intervention: FIB-4 pathway
Number of subjects: 1929
Study 38061448 — intervention group
Group type: COMPARATOR
Intervention: RSP
Number of subjects: 1929
Study 38061553 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 77
Study 38061553 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 77
Study 38061553 — intervention group
Group type: COMPARATOR
Intervention: EMDR therapy and ST
Number of subjects: 77
Study 38061630 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 262
Study 38061630 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step involvement
Number of subjects: 262
Study 38061630 — intervention group
Group type: COMPARATOR
Intervention: Social support
Number of subjects: 262
Study 38061681 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) for 4 days
Number of subjects: 95
Study 38061681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 38061681 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 95
Study 38061786 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Mindfulness-Oriented Recovery Enhancement (MORE) plus usual care
Number of subjects: 154
Study 38061786 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 38061976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic PSMA PET/CT
Number of subjects: 660
Study 38061976 — intervention group
Group type: COMPARATOR
Intervention: Template transperineal prostate biopsies
Number of subjects: 660
Study 38061976 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of transperineal prostate biopsy
Number of subjects: 660
Study 38062124 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (IT) with novel agent-based triplet/quadruplet
Number of subjects: 3700
Study 38062124 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on baseline factors
Number of subjects: 3700
Study 38062132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Number of subjects: 689
Study 38062132 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 689
Study 38062157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for obesity for 8 weeks
Number of subjects: 45
Study 38062221 — intervention group
Group type: EXPERIMENTAL
Intervention: LTBI-ASSIST Tool
Number of subjects: 130